AstraZeneca is creating a separate section on vaccines and antibody therapies led by Iskra Reik CEO, the pharmaceutical company announced today, as it focuses on its Covid-19 vaccine and the development of coronavirus therapies.
Reuters reported in July that the Anglo-Swedish company was considering options for its vaccine business and that more clarity was expected by the end of 2021.
The new unit will combine research and development, production, marketing and medical teams, an AstraZeneca spokesman said.
“The team will be committed to our Covid-19 vaccine, the combination of long-acting antibodies we are developing as well as the vaccine we are developing to treat many variants of concern, and our existing portfolio for viral respiratory diseases,” he added. representative.
The news was first reported by the Financial Times.
Source: AMPE
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
